189 related articles for article (PubMed ID: 37204724)
1. Assays to Monitor Bivalirudin.
Davidson S
Methods Mol Biol; 2023; 2663():369-380. PubMed ID: 37204724
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
[TBL] [Abstract][Full Text] [Related]
3. Bivalirudin: a direct thrombin inhibitor.
Gladwell TD
Clin Ther; 2002 Jan; 24(1):38-58. PubMed ID: 11833835
[TBL] [Abstract][Full Text] [Related]
4. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin.
Tanaka KA; Szlam F; Sun HY; Taketomi T; Levy JH
Anesth Analg; 2007 Oct; 105(4):933-9, table of contents. PubMed ID: 17898368
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients.
Beyer JT; Lind SE; Fisher S; Trujillo TC; Wempe MF; Kiser TH
J Thromb Thrombolysis; 2020 Feb; 49(2):259-267. PubMed ID: 31559512
[TBL] [Abstract][Full Text] [Related]
6. Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
Van Cott EM; Roberts AJ; Dager WE
Semin Thromb Hemost; 2017 Apr; 43(3):270-276. PubMed ID: 28052306
[TBL] [Abstract][Full Text] [Related]
7. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
Ann Pharmacother; 2004 Sep; 38(9):1383-8. PubMed ID: 15238620
[TBL] [Abstract][Full Text] [Related]
8. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?
Curvers J; van de Kerkhof D; Stroobants AK; van den Dool EJ; Scharnhorst V
Am J Clin Pathol; 2012 Oct; 138(4):551-8. PubMed ID: 23010710
[TBL] [Abstract][Full Text] [Related]
9. Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays.
Wakui M; Fujimori Y; Nakamura S; Kondo Y; Kuroda Y; Oka S; Nakagawa T; Katagiri H; Murata M
J Clin Pathol; 2019 Dec; 72(12):817-824. PubMed ID: 31366633
[TBL] [Abstract][Full Text] [Related]
10. The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia.
Guy S; Kitchen S; Laidlaw S; Cooper P; Woolley A; Maclean R
Br J Haematol; 2008 Jul; 142(3):466-8. PubMed ID: 18510685
[TBL] [Abstract][Full Text] [Related]
11. Chromogenic and Clot-Based Bivalirudin Assays for Monitoring Anticoagulation.
Raghavendran P; Tillman BF; Wheeler AP; Gailani D
J Appl Lab Med; 2023 Nov; 8(6):1074-1083. PubMed ID: 37811688
[TBL] [Abstract][Full Text] [Related]
12. Bivalirudin: pharmacology and clinical applications.
Shammas NW
Cardiovasc Drug Rev; 2005; 23(4):345-60. PubMed ID: 16614733
[TBL] [Abstract][Full Text] [Related]
13. How to best monitor bivalirudin anticoagulant effect for ECMO and VAD-Comparison of four assay methods.
Teruya J; Bruzdoski K; Hensch L; Hui SR; Kostousov V
Int J Lab Hematol; 2022 Jun; 44(3):589-594. PubMed ID: 34939341
[TBL] [Abstract][Full Text] [Related]
14. Bivalirudin: a review of its use in patients undergoing percutaneous coronary intervention.
Moen MD; Keating GM; Wellington K
Drugs; 2005; 65(13):1869-91. PubMed ID: 16114983
[TBL] [Abstract][Full Text] [Related]
15. Measurement of patients' bivalirudin plasma levels by a thrombelastograph ecarin clotting time assay: a comparison to a standard activated clotting time.
Carroll RC; Chavez JJ; Simmons JW; Snider CC; Wortham DC; Bresee SJ; Cohen E
Anesth Analg; 2006 May; 102(5):1316-9. PubMed ID: 16632802
[TBL] [Abstract][Full Text] [Related]
16. Bivalirudin.
Warkentin TE; Greinacher A; Koster A
Thromb Haemost; 2008 May; 99(5):830-9. PubMed ID: 18449412
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of Argatroban in Critically Ill Patients: A Prospective Study Comparing Activated Partial Thromboplastin Time, Point-of-Care Viscoelastic Testing with Ecarin Clotting Time and Diluted Thrombin Time to Mass Spectrometry.
Heubner L; Oertel R; Tiebel O; Mehlig-Warnecke N; Beyer-Westendorf J; Mirus M; Roessler M; Renner B; Spieth PM
Anesthesiology; 2024 Feb; 140(2):261-271. PubMed ID: 37787760
[TBL] [Abstract][Full Text] [Related]
18. Bivalirudin: a new approach to anticoagulation.
Nawarskas JJ; Anderson JR
Heart Dis; 2001; 3(2):131-7. PubMed ID: 11975781
[TBL] [Abstract][Full Text] [Related]
19. Successful use of a bivalirudin treatment protocol to prevent extracorporeal thrombosis in ambulatory hemodialysis patients with heparin-induced thrombocytopenia.
Al-Ali FS; Elsayed M; Khalifa S; Abdulla AE; Tolba H; Bouanane H; Ibrahim R; Hamad A
Hemodial Int; 2016 Apr; 20(2):204-7. PubMed ID: 26501237
[TBL] [Abstract][Full Text] [Related]
20. Microfluidic Point-of-Care Ecarin-Based Clotting and Chromogenic Assays for Monitoring Direct Thrombin Inhibitors.
Alouidor B; Sweeney RE; Tat T; Wong RK; Yoon JY
J Extra Corpor Technol; 2019 Mar; 51(1):29-37. PubMed ID: 30936586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
